
Ascendis Pharma gains full rights to TransCon tech, launches $400M buyback, and posts positive trial data.
Ascendis Pharma A/S regained full control of its TransCon technology for metabolic diseases from Novo Nordisk, allowing it to independently develop and sell treatments, including for obesity. The company also authorized a $400 million share repurchas...





